Bone Marrow Aspirate Concentrate in Treating Mandibular Cystic Defects

Hams Hamed Abdelrahman16 enrolled

Overview

Mandibular cystic defect healing is a complex process. Various methods have been developed to shorten the bone regeneration time and improve its quality. Autogenous grafting is the gold standard for filling cystic defects due to the osteogenesis property provided by the viable cells but is related to donor site morbidity. Allografts and Xenografts are used for the same purpose. However, the increased cost is their main disadvantage. Bone marrow aspirate concentrate is now used to enhance the healing and regeneration process in many areas of the body with no morbidity and low cost.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Mandible Cyst

Interventions

Enucleation and filling by Bone marrow aspirateOTHER

The iliac crest is palpated along its widest part forming the iliac tubercle ( 5-6 cm posterior to the anterior superior iliac spine), then a 5 mm incision is made 3-4 cm posterior to the ASIS directly on the crest. The needle is advanced between the outer and inner plates of the ileum for a 4-6 cm into the cancellous bone and 10 ml of bone marrow is aspirated. Bone marrow aspirate is processed by a dual centrifugation technique.

Conventional enucleation onlyOTHER

patients were treated conventionally by enucleation and plain collagen sponge only.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients suffering from mandibular cystic defect. * Cystic defect width of 4-8 cm that requires removal under general anesthesia. Exclusion Criteria: * Medically compromised patients contradicting operation. * Previously enucleated lesions. * Previous surgery, tumor, infection to the pelvis affecting the anterior iliac crest. * Infected Cysts

Locations (1)

Outpatient Clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alexandria University, Egypt

Alexandria, Azarita, Egypt

Outcomes

Primary Outcomes

Change in pain scores

pain was assessed through a 10-point Visual Analogue Scale (VAS) the scores are categorizied as follows: (0-1= None, 2-4= Mild, 5-7= Moderate, 8-10= Severe)

Time frame: 1st day, 1 week, 4 weeks, 6 weeks

Change in bone density

An immediate postoperative CBCT was be obtained, followed by another one taken after 3 and 6 months postoperatively. The Region of Interest (ROI) feature was used to estimate the mean bone density in the immediate and 6 months scans. The mean bone density in the 6 months CBCT-scan was compared with the immediate postoperative and the preoperative scans and the mean difference between the scans was calculated.

Time frame: at baseline, 3 months, 6 months

Secondary Outcomes

change in wound dehiscence

any signs of wound dehiscence were observed

Time frame: 1st day, 1 week, 4 weeks, 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.